Chimeric VLPs Bearing VP60 from Two Serotypes of
RHDV
Trichoplusia ni
baculovirus
bivalent vaccine
calicivirus
chimeric VLP
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
09 Sep 2021
09 Sep 2021
Historique:
received:
04
08
2021
revised:
26
08
2021
accepted:
31
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
The VP60 capsid protein from rabbit haemorrhagic disease virus (RHDV), the causative agent of one of the most economically important disease in rabbits worldwide, forms virus-like particles (VLPs) when expressed using heterologous protein expression systems such as recombinant baculovirus, yeasts, plants or mammalian cell cultures. To prevent RHDV dissemination, it would be beneficial to develop a bivalent vaccine including both RHDV GI.1- and RHDV GI.2-derived VLPs to achieve robust immunisation against both serotypes. In the present work, we developed a strategy of production of a dual-serving RHDV vaccine co-expressing the VP60 proteins from the two RHDV predominant serotypes using CrisBio technology, which uses
Identifiants
pubmed: 34579243
pii: vaccines9091005
doi: 10.3390/vaccines9091005
pmc: PMC8472679
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Alternative Gene Expression S.L.
ID : AGL2013-48550-C2-1-R
Organisme : Spanish Ministry for Science Innovation and Universities
ID : AGL2017-83395-R
Organisme : Spanish Ministry for Science Innovation and Universities
ID : PID2020-120349RB-100
Références
Virology. 2007 Aug 1;364(2):422-30
pubmed: 17434554
J Mol Biol. 1994 Jul 15;240(3):256-64
pubmed: 8028008
Vet Rec. 2017 Apr 29;180(17):426
pubmed: 28341721
J Virol. 1990 Jul;64(7):3331-6
pubmed: 2352325
Virol J. 2007 Oct 02;4:96
pubmed: 17910765
Methods. 2006 Sep;40(1):60-5
pubmed: 16997714
Vet Rec. 2011 Feb 5;168(5):137-8
pubmed: 21493491
J Gen Virol. 2002 Oct;83(Pt 10):2461-2467
pubmed: 12237428
PLoS One. 2015 Oct 12;10(10):e0140039
pubmed: 26458221
J Virol. 1999 May;73(5):4452-5
pubmed: 10196345
Virology. 2001 Feb 15;280(2):283-91
pubmed: 11162842
J Virol. 2018 Jan 2;92(2):
pubmed: 29093089
Expert Rev Vaccines. 2007 Jun;6(3):381-90
pubmed: 17542753
Vaccine. 2012 Dec 17;31(1):58-83
pubmed: 23142589
Sci Rep. 2016 Aug 23;6:31844
pubmed: 27549017
Virology. 1991 Oct;184(2):664-76
pubmed: 1840711
J Biotechnol. 2020;324S:100019
pubmed: 34154729
Virus Res. 1993 Mar;27(3):219-28
pubmed: 8488721
Vaccine. 1997 Jan;15(1):90-6
pubmed: 9041672
J Gen Virol. 1994 Sep;75 ( Pt 9):2409-13
pubmed: 8077941
J Gen Virol. 1997 Sep;78 ( Pt 9):2315-8
pubmed: 9292020
NPJ Vaccines. 2020 Dec 14;5(1):110
pubmed: 33318483
J Infect Dis. 2014 Dec 1;210(11):1763-71
pubmed: 24951828
Clin Ther. 2017 Aug;39(8):1537-1549
pubmed: 28756066
J Virol. 2009 Dec;83(23):12129-38
pubmed: 19759153
Rev Sci Tech. 2002 Aug;21(2):347-58
pubmed: 11974620
Emerg Infect Dis. 2012 Dec;18(12):2009-12
pubmed: 23171812
J Virol. 1994 Oct;68(10):6794-8
pubmed: 8084017
PLoS One. 2014 May 13;9(5):e96562
pubmed: 24824596
Vaccine. 1996 Apr;14(6):506-10
pubmed: 8782348
J Virol. 1995 Sep;69(9):5812-5
pubmed: 7637026
J Virol Methods. 2018 Jan;251:118-122
pubmed: 29024672
Vet Microbiol. 2018 Jun;219:87-95
pubmed: 29778210
J Virol. 1990 Aug;64(8):4013-5
pubmed: 2164609
J Gen Virol. 2017 Jul;98(7):1658-1666
pubmed: 28714849
Antiviral Res. 2013 Mar;97(3):227-31
pubmed: 23295353
J Virol. 2014 Jul;88(13):7256-66
pubmed: 24741081
J Virol. 1996 Aug;70(8):5061-6
pubmed: 8764013
Vet Microbiol. 2014 Feb 21;169(1-2):67-73
pubmed: 24461551
Mol Immunol. 2005 Feb;42(2):259-77
pubmed: 15488613
Pharmaceutics. 2019 Jan 10;11(1):
pubmed: 30634665
Arch Virol. 1995;140(6):1095-1108
pubmed: 7541982
Rev Sci Tech. 1991 Jun;10(2):459-80
pubmed: 1760586
Virus Res. 1995 Dec;39(2-3):119-28
pubmed: 8837879
Virus Res. 1992 Oct;26(1):33-40
pubmed: 1441736
Virology. 2000 Oct 25;276(2):349-63
pubmed: 11040126